Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Microbicides news

Show

From To
TAF: Quick-dissolve combination PrEP insert is effective against HIV infections in monkeys; intermittent solo pill less so

Two studies in monkeys of experimental pre-exposure prophylaxis (PrEP) regimens featuring the drug tenofovir alafenamide (TAF) produced differing results when presented at last week’s Conference on Retroviruses

Published
13 March 2019
By
Gus Cairns
REACH trial comparing vaginal ring to PrEP for HIV prevention begins

The NIH announced the start of a clinical trial that will explore the preference among adolescent girls and young women between pre-exposure prophylaxis, or PrEP, and a vaginal ring for HIV prevention.

Published
24 February 2019
From
Healio
Emerging options: Doctors and advocates discuss treatment and prevention breakthroughs on the horizon

Long-acting injectables, implantables, the dapivirine ring, vaccines, antibodies, rectal douches, and two-drug regimens.

Published
30 January 2019
From
Positively Aware
Going local – prevention conference hears about rings, douches, and soluble suppositories

Last week’s HIV Research for Prevention conference (HIVR4P 2018) in Madrid heard a lot about oral pre-exposure prophylaxis (PrEP): not only its efficacy but also

Published
31 October 2018
By
Gus Cairns
Beyond Truvada – what is the future of PrEP?

Oral pre-exposure prophylaxis (PrEP) based on tenofovir disoproxil fumarate/emtricitabine (Truvada) has set a high bar for prevention effectiveness, but a range of alternative PrEP products are in

Published
31 October 2018
By
Roger Pebody
Vaginal rings, films, inserts or gels – it’s all about choice

There is no single HIV prevention technology which suits everyone – young African women who have tried four different vaginal products make different choices, with no one

Published
26 October 2018
By
Roger Pebody
Making Clinical Trials of PrEP More Inclusive of Women, No Matter Their Pregnancy Status

Three new trials of HIV prevention drugs seek to answer directly a question that researchers inside and outside the field of HIV have explicitly avoided for years: How do drugs work -- and are they safe -- in pregnant and breastfeeding women?

Published
01 October 2018
From
The Body Pro
First Multipurpose Gel Designed to Prevent HIV, HSV, and HPV Simultaneously in Women and Men Advances in Clinical Trials

A new Phase I study of the Population Council’s multipurpose prevention technology (MPT) gel PC-1005, launching this week, will examine the safety of the gel when used rectally by both men and women. If proven effective, PC-1005 gel would be the first product to prevent three incurable sexually transmitted infections (STIs)—HIV, herpes simplex virus (HSV), and human papillomavirus (HPV)—when used either vaginally or rectally.

Published
25 June 2018
From
Population Council
Vaginal implant might stop HIV transmission

Scientists at the University of Waterloo have developed a promising new medical device that could help protect women from HIV. The technology consists of a vaginal implant that basically reduces the amount of targets the virus can latch onto during sex, and may prove a more effective measure than some anti-HIV drugs or condoms in fending off infections.

Published
17 April 2018
From
New Atlas
CROI 2018: Highlights and what’s next for advocates

Historically, CROI is heavy on basic science and early-phase research. Data from these types of studies were still prominent in 2018, but this year the meeting also broadened its lens from the lab to the ways that different strategies are, or might, have an impact in the context of people's complex lives.

Published
27 March 2018
From
AVAC
← First12345...26Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.